BSLN.SW Stock — Price, Charts & Analysis

Basilea Pharmaceutica AG (BSLN.SW) has a trailing P/E of 20.89x and a forward P/E of 15.30x. This places BSLN.SW in a moderate earnings multiple territory based on the valuation data currently available on Worldtickers.

BSLN.SW trades with 20.89x earnings on Worldtickers. Use valuation together with growth, balance sheet strength, and risk before deciding whether BSLN.SW looks overvalued or undervalued.

BSLN.SW's P/E of 20.89x should be judged against Healthcare peers, growth rate, margins, and balance sheet quality. A lower P/E may indicate value, while a higher P/E often means investors expect stronger future growth.

BSLN.SW's trailing EPS is CHF 3.14 and forward EPS is CHF 4.29. Reported earnings growth is 64.40%, which helps show current profit momentum.

EPS, or earnings per share, shows how much profit Basilea Pharmaceutica AG generated for each share. BSLN.SW's trailing EPS is CHF 3.14, and investors usually prefer EPS that is positive and growing over time.

Basilea Pharmaceutica AG has a market cap of CHF 811.91M, making BSLN.SW a small-cap stock based on the current market value shown on Worldtickers.

BSLN.SW's latest stock price on Worldtickers is CHF 65.60. The latest move is CHF 3.10 or 4.96%. Use the live quote, chart, volume, and 52-week range to judge the current trading context.

BSLN.SW's quote includes a latest price of CHF 65.60. The market open is CHF 62.80. Previous close is CHF 62.50. The intraday range is CHF 62.80 to CHF 65.60.

BSLN.SW is up in the latest quote, with a move of CHF 3.10 or 4.96%. To understand the reason, compare this move with news, earnings updates, analyst changes, sector performance, and market-wide direction.

BSLN.SW generated CHF 247.42M in trailing revenue. Revenue growth is 14.50%, which helps show whether demand is expanding or slowing.

BSLN.SW's revenue growth is 14.50%, which is a strong demand signal in the latest available data. Investors usually compare revenue growth with margin trends and valuation to judge whether growth is profitable.

Yes, BSLN.SW shows positive profitability metrics in the latest data available on Worldtickers. Net income to common shareholders is CHF 52.38M.

Gross margin is 38.51%. Margins show how efficiently Basilea Pharmaceutica AG turns revenue into profit.

Basilea Pharmaceutica AG carries CHF 83.44M and holds CHF 173.05M in cash.

BSLN.SW holds CHF 173.05M on its balance sheet.

BSLN.SW's book value per share is CHF 13.13.

Institutions hold 30.88% of BSLN.SW shares. Insiders hold 0.62% of shares. Ownership mix helps investors understand how much of Basilea Pharmaceutica AG is held by professional investors and company insiders.

BSLN.SW has 12.38M shares outstanding. Float shares are 12.32M. Share count affects market cap, EPS, ownership percentages, and the impact of buybacks or dilution.

Insider activity can be useful context for BSLN.SW, especially when multiple executives buy shares with their own money. Insider selling is harder to interpret because executives may sell for taxes, diversification, or planned compensation reasons.

Forward EPS for BSLN.SW is CHF 4.29. Earnings growth is 64.40%. Revenue growth is 14.50%. For earnings, investors usually watch EPS, revenue, margins, guidance, and management commentary.

BSLN.SW's trailing EPS is CHF 3.14. Forward EPS is CHF 4.29. Use the earnings section on the page to compare reported results, estimates, and trend changes when those datasets are available.

BSLN.SW is in the Healthcare sector. Its earnings multiple is 20.89x. Its latest displayed growth metric is 14.50%. Compare these figures with sector peers before deciding whether Basilea Pharmaceutica AG is stronger or weaker than average.

BSLN.SW trades at CHF 65.60. The stock trades at 20.89x earnings. Whether to invest depends on your risk tolerance, time horizon, diversification, and view of Basilea Pharmaceutica AG's fundamentals.

BSLN.SW risks include company execution, valuation, competition in Healthcare, interest rates, and broad market volatility. Beta is 0.41, which helps estimate market sensitivity. No single stock should be evaluated without portfolio context.

BSLN.SW should be compared with companies in Biotechnology. Its earnings multiple is 20.89x. Useful comparison points include revenue growth, margins, debt, cash flow, valuation, analyst targets, and price momentum.

Basilea Pharmaceutica AG (BSLN.SW) operates in Healthcare, specifically Biotechnology. Basilea Pharmaceutica AG is a Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections. The company offers Cresemba (isavuconazole), an intravenous and oral antifungal for the treatment of invasive aspergillosis and mucormycosis; and Zevtera (ceftobiprole), an antibiotic for the treatment of pneumonia, Staphylococcus aureus bacteremia (SAB), acute bacterial skin, community-acquired bacterial pneumonia, and skin structure infections (ABSSS

BSLN.SW trades on Swiss. Exchange context matters because trading hours, liquidity, currency, and settlement rules can differ across markets.

BSLN.SW stock is priced in CHF on Worldtickers. Currency matters for international investors because exchange-rate moves can affect local-currency returns.

Basilea Pharmaceutica AG's official website listed on Worldtickers is www.basilea.com. Investor relations pages are useful for earnings releases, annual reports, filings, and shareholder presentations.

Basilea Pharmaceutica AG employs about 200 people based on the latest company profile data available on Worldtickers. Workforce size helps investors understand company scale and operating complexity.

Basilea Pharmaceutica AG is headquartered in Allschwil, Switzerland. Headquarters location can matter for currency, regulation, tax, labor market, and regional economic exposure.

BSLN.SW is in the Healthcare sector and the Biotechnology industry. Sector context helps investors compare valuation, growth, margins, and risk against similar companies.

BSLN.SW has traded between CHF 44.70 and CHF 65.60 over the past 52 weeks. At CHF 65.60, it is 0.00% below the high and 46.76% above the low. The 52-week range helps gauge long-term price momentum.

BSLN.SW is above both its 50-day and 200-day moving averages, which is a common uptrend signal. Its 50-day moving average is CHF 52.41 and its 200-day moving average is CHF 52.60.

BSLN.SW's RSI is 85.01. Readings below 30 are commonly viewed as oversold, above 70 as overbought, and the current reading suggests a overbought momentum setup.

BSLN.SW's latest RSI reading is 85.01, which points to overbought momentum today. Traders usually confirm RSI with volume, trend, and nearby support or resistance.

Key support for BSLN.SW is near CHF 50.40. Key resistance is near CHF 59.60. Breaks above resistance or below support can change the short-term technical setup.

BSLN.SW's nearest reported support level is CHF 50.40. A clean break below support can weaken the short-term setup, while repeated bounces can show demand.

BSLN.SW's nearest reported resistance level is CHF 59.60. A breakout above resistance can improve momentum, especially when volume confirms the move.

BSLN.SW trades about 32.85K shares daily on average. The latest displayed volume is 174.65K shares. Volume helps show liquidity and whether trading interest is unusually high or low.

BSLN.SW's MACD is 1.03, which is a positive momentum reading. MACD should be reviewed with price trend, moving averages, RSI, volume, and support or resistance levels.

BSLN.SW is above both its 50-day and 200-day moving averages, which is a common uptrend signal. RSI is 85.01 (overbought). MACD is bullish. Nearest support is around CHF 50.40. Resistance is around CHF 59.60. A buy decision should also consider valuation, earnings quality, risk tolerance, and position sizing.

MA20 is CHF 53.03 (17.87% from price). MA50 is CHF 52.41 (19.25% from price). MA200 is CHF 52.60 (18.82% from price). The moving-average stack helps separate short-term momentum from long-term trend risk.

The server report currently confirms daily moving-average levels rather than a separate EMA-only value. BSLN.SW's MA20 is CHF 53.03. MA50 is CHF 52.41. For EMA-specific overlays, use the live chart indicators and compare EMA direction with RSI, MACD, volume, support, and resistance.

BSLN.SW's pivot is near CHF 58.77. Support is near CHF 50.40. Resistance is near CHF 59.60. Price holding above pivot can support a constructive setup, while rejection near resistance can cap momentum.

The next lower support zone for BSLN.SW is near CHF 57.80. These levels help define risk and possible follow-through zones after a breakout or breakdown.

BSLN.SW's Bollinger range is roughly CHF 47.36 to CHF 58.69. Band width is near 21.38%. Price near the upper band can show stretched upside momentum, while price near the lower band can show downside pressure or a possible mean-reversion zone.

BSLN.SW's ATR-based typical daily range is about 2.54%. ATR helps size risk because wider ranges usually require wider stops or smaller position sizes.

Latest volume is 174.65K shares. Average volume is about 32.85K shares. Breakouts with rising relative volume are usually more reliable than moves on light participation.

BSLN.SW's all-time high shown on Worldtickers is CHF 284.75. Its all-time low is CHF 28.55. All-time levels provide long-range context, but recent fundamentals and market conditions matter more for current decisions.

BSLN.SW has a beta of 0.41, meaning it has historically been less volatile than the broad market. Beta is useful for judging how much a stock may move during broad market swings.